Mutations of the epidermal growth factor receptor (EGFR) tyrosine kinase domain lead to constitutively active oncogenic signals and are the most frequent driving mutations for NSCLC [2,3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.